

Risk factors of Non-Alcoholic Fatty Liver Diseases in Bangladesh: A Tertiary Care Hospital Study

Abstract

Background: NAFLD (non-alcoholic fatty liver disease) is a highly frequent condition. Data on the epidemiology of non-alcoholic fatty liver disease (NAFLD) is scarce, especially in underdeveloped nations like Bangladesh. Although many people have risk factors for NAFLD, the majority do not progress to severe liver disease such as cirrhosis, hepatic decompensation, or hepatocellular carcinoma. It's critical to identify those who are at a high risk of developing these complications so that risk factors can be identified and illness progression can be avoided. **Aim of the study:** The study aims to analyze the risk factors of non-alcoholic fatty liver disease in a tertiary care hospital of Bangladesh. **Method:** This cross-sectional study was conducted from September 2019 to February 2020 at Dhaka Medical College Hospital, Bangladesh. This study was purposefully conducted among 35 participants. **Results:** Among 35 participants, the mean age of the participants were 38.89 ± 8.50 years. Maximum participants (80%) were female and housewife (68.6%). And 60% participant's socioeconomic status was middle class state. Maximum (48.6%) participants had diabetes mellitus (DM) and obesity (42.9%). Their mean body weight was 72.74 ± 8.74 and mean body height was 61.37 ± 2.67 . **Conclusion:** In Bangladesh, NAFLD is becoming the leading cause of chronic liver disease. This necessitates the attention of health policymakers and physicians to investigate and battle this threat as soon as possible. To control and prevent NAFLD and its negative health implications, public health actions are required.

Keywords: Non-Alcoholic, Fatty Liver Disease, Risk Factors, Tertiary Care Hospital.

INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) is a condition in which the liver accumulates excessive amounts of lipid defined as the presence of lipid in more than 5% of hepatocytes or a lipid content greater than 5% of liver weight in people who consume little less than 20 g of alcohol per day or no alcohol.^{1,2} It is the leading cause of chronic liver disease.³ Nonalcoholic steatohepatitis (NASH) is a condition in which NAFLD is combined with liver cell damage and inflammation.² About 30% of people with NAFLD develop NASH, which can lead to fibrosis, cirrhosis, and possibly hepatocellular carcinoma (HCC) if left untreated.⁴ Nonalcoholic fatty liver disease prevalence has risen dramatically in the Asia-Pacific area over the years, affecting up to 30% of the general population.⁵ The prevalence of NAFLD in adults has been rising in both developing and developed Asian nations.⁶ Metabolic syndrome is a major risk factor for NAFLD in adults from South Asia, with Bangladeshi ethnicity being a significant independent risk factor.³ Because of its high prevalence, potential to advance to severe liver disease, and link to serious cardio-metabolic abnormalities such as type 2 diabetes mellitus (T2DM), metabolic syndrome, and coronary heart disease, NAFLD has become a major public health concern. NAFLD has become the most common cause of chronic liver disease in western countries, as well as lower BMI places such as Asia, due to the rising prevalence of obesity, diabetes, and metabolic syndrome in the general population. Recent socioeconomic developments, such as rising wealth and lifestyle modifications, have led in the emergence of a noncommunicable disease epidemic, such as NAFLD. Nonalcoholic fatty liver disease was the most commonly reported liver disease, with Bangladeshi individuals being the most affected. Bangladeshi ethnicity, diabetes, increased BMI, hypertension, and hypercholesterolemia were all found to be independent risk factors for NAFLD in a multivariate study. The prevalence of NAFLD in the general population of Bangladesh has been reported to range from 4 to 18.4%, with diabetic individuals having a

46 prevalence of 49.8%^{7, 8}. In their rural population-based investigation, Rahman et al found a prevalence of
47 18.4%, with a higher prevalence of 59.4% in diabetes patients⁸. Diabetes, obesity (BMI>25), increased
48 waist circumference, and hypertriglyceridemia were all found to be independent risk factors for the
49 development of NAFLD in this study⁸. After chronic hepatitis B, this is the second most common reason
50 for a hepatology out-patient visit in the country.⁹ As a result, the nature and scope of the NAFLD problem
51 in Bangladesh must be seriously addressed.

52 **OBJECTIVE**

53 The aim of the study was to analyze the **risk factors** of non-alcoholic fatty liver disease in a tertiary care
54 hospital of Bangladesh.

55 **Materials and methods**

56 **Methods**

57 This cross-sectional study was carried out in the OPD, Department of Hepatology, Dhaka Medical College
58 Hospital, Bangladesh in a total of 35 individuals between September 2019 to February 2020. Data
59 collected from the participants in a prescribed protocol. Each applicant had received an informed,
60 voluntary written consent before enrolment. A datasheet has included detailed medical history and
61 physical examination of the study population. The monitoring of each individual's blood pressure was
62 tested by evaluating the Blood Pressure in various settings. The study population's body mass index
63 (BMI) was calculated by measuring body height and weight with the subject standing motionless on the
64 weighing scale, feet about 15 cm apart, and weight distributed equally on each leg. The methods for
65 assessment of fibrosis and steatosis in our patients was done by FibroScan. It is a specialized ultrasound
66 machine for liver that measures fibrosis (scarring) and steatosis (fatty change) in liver.

67 **Inclusion criteria**

- 68
- 69 • Patients not more than 60 years of age.
- 70 • Patients with the history of NAFLD.
- 71 • Patients who wanted to participate in this study
- 72

73 **The procedure for collecting and analyzing data**

74 Data were entered in the computer using SPSS version 21.0, calculation of percentage resistance within a
75 95% confidence interval (CI). The level of significance was considered as a “P” value less than 0.05 and
76 double-checked before analysis.

77

78 **RESULTS**

79 Table 1 shows the demographic characteristics of the participants of the study. Among 35 participants,
80 48.6% participants were below 40 years old and 51.4% were between 40 to 60 years old. The mean age of
81 the participants were 38.89 ± 8.50 years. Maximum participants (80%) were female and housewife
82 (68.6%). Maximum participants (82.8%) we're not used to with exercise. And 60% participant's
83 socioeconomic status was middle class state.

84

Table 1: Demographic status of participants (N=35)

Variables	n	%	Mean ± SD
Age group			
<40 yrs.	17	48.6	
40-60 yrs.	18	51.4	
Mean in Age	35		38.89 ± 8.50
Gender			
Male	7	20.0	
Female	28	80.0	
Rice 1 time	3	8.6	
Rice 2 times	13	37.1	
Rice 3 times	19	54.3	
Exercise			
Yes	5	14.3	
No	29	82.8	
Occasional	1	2.9	

85

86 Table 2 showed the status of the risk factors among the participants. In our study, maximum (48.6%)
 87 participants had diabetes mellitus and obesity (42.9%). The HBs Ag and Anti-HCV was negative among
 88 all participants. Their mean body weight was 72.74 ± 8.74 and mean body height was 61.37 ± 2.67 .

89

Table 2: Risk factors status of participants (N=35)

Variables	n	%	Mean ± SD
Risk factors			
DM	17	48.6	
Obesity	15	42.9	
Hyperlipidemia	9	25.7	
HTN	8	22.9	
IHD	2	5.7	
Thyroid disorders	2	5.7	
HBs Ag			
Positive	0	0.0	
Negative	35	100.0	
Anti-HCV			
Positive	0	00	
Negative	35	100.0	
Body (BMI)			
Body weight			72.74 ± 8.74
Body Height			61.37 ± 2.67

90 *DM- Diabetes mellitus, HTN- Hypertension, IHD: Ischemic Heart Disease, HBs Ag: Hepatitis B surface
 91 antigen, Anti-HCV: Antibody to hepatitis C virus, BMI: Body Mass Index.

92 Table 3 showed the status of the investigations done among the participants. The mean amount of S.
 93 Bilirubin, SGPT, SGOT, ALK PHOS, RBS, HBA1C, TSH, and Lipid profile C, Lipid profile H, Lipid
 94 profile L and Lipid profile T.

95 **Table 3:** Investigations status of participants (N=35)

Variables	Mean ± SD	95% Confidence Interval of the Difference		P-Value
		Lower	Upper	
S. Bilirubin	0.53 ± 0.20	0.46	0.60	0.544
SGPT	50.89 ± 24.82	42.36	59.41	0.011
SGOT	42.94 ± 23.92	34.73	51.16	0.116
ALK PHOS	56.63 ± 24.98	48.05	65.21	0.968
RBS	6.62 ± 2.99	5.60	7.65	0.231
HBA1c	5.58 ± 1.75	4.98	6.18	0.243
TSH	2.40 ± 1.33	1.94	2.85	0.805
Lipid profile C	207.14 ± 56.82	187.63	226.66	0.161
Lipid profile H	42.97 ± 10.72	39.29	46.65	0.084
Lipid profile L	120.09 ± 45.91	104.32	135.85	0.137
Lipid profile T	214.54 ± 108.25	177.36	251.73	0.937

96 * SGPT: Serum Glutamic Pyruvic Transaminase, SGOT: Serum Glutamic-oxaloacetic Transaminase,
 97 ALK PHOS: Alkaline phosphatase, RBS: Random blood sugar, HBA1c: Hemoglobin A1c, TSH: Thyroid
 98 stimulating hormone.

99 Table 3 A showed, among 35 participants 60% was SGPT <42 and rest 40% was SGPT >42. See below-

100
 101

Table 3A: SGPT Distribution of participants (N=35)

Variables	n	%
SGPT <42	21	60.0
SGPT >42	14	40.0

102

103 Table 4 showed the Hepatic fibrosis status among the participants. Here, mild level was in 94.4% patients,
 104 moderate level was in 5.7% patients and severe level was observed in 2.9% patients. See the table below-

105


106 **Table 4:** Hepatic fibrosis status among the participants (N=35)

Hepatic Fibrosis	Fatty liver score	
	n	%
Mild (1-8.6) [stage 0, 1]	32	94.4
Moderate (8.6-11.7) [stage 2,3]	2	5.7
Severe (11.7-75) [stage 4]	1	2.9

107

108 The stiffness status of participants are shown in figure I. See the different levels of stiffness observed in
 109 our patients, in the figure below-

110



111

112

Figure I: Stiffness status of participants

113 Table 5 showed that among total participants more than fifty percent (57.2%) was in stage four of severe.
 114 And mild level was observed in 11.4% patients followed by 31.4% patients with moderate level of hepatic
 115 steatosis. See the table below-

116

Table 5: Hepatic steatosis status among the participants (N=35)

Hepatic steatosis (Fat content in liver)	Fatty liver score	
	n	%
Mild (1-270) [stage 0, 1]	4	11.4
Moderate (270-302) [stage 2]	11	31.4
Severe (302-400) [stage 3]	20	57.2

117

118 Figure II showed the fibro scan status of participants of this study. It showed that maximum patients had
 119 stage 3 according to their status and minimum number of patients had stage 1 status according to their
 120 status. See the figure below-




Figure II: Fibro scan status of participants

121

122

123 DISCUSSION

124 Nonalcoholic fatty liver disease is a highly common condition that affects one out of every three to five
 125 people and one out of every ten children¹⁰. Obesity is regarded to be the leading cause of fatty liver
 126 infiltration. In our study, maximum (48.6%) participants had diabetes mellitus and obesity (42.9%). Their
 127 mean body weight was 72.74 ± 8.74 and mean body height was 61.37 ± 2.67 . According to some
 128 specialists, fatty liver affects roughly two-thirds of obese adults and half of obese children¹¹. Type 2
 129 diabetes and other insulin-resistant diseases, such as polycystic ovarian syndrome, are well-known risk
 130 factors for the development of fatty liver and NASH¹¹. With some minor modifications, the risk factors
 131 for NAFLD in Bangladesh appear to be similar to those in the Western world. The main risk factors
 132 include age, obesity, insulin resistance, and the general development of metabolic syndrome^{12, 13}. HTN,
 133 waist circumference, BMI, and insulin resistance have all been linked in multiple population-based
 134 studies from South Asia¹⁴. BMI, homeostatic model assessment of insulin resistance (HOMA-IR), waist-
 135 hip ratio, diabetes, HTN, family history of metabolic syndrome, and sleep apnea were all identified as risk
 136 factors for NAFLD in a study conducted in India in 2015^{14,15}. Furthermore, in India, specific dietary
 137 behaviors were linked to NAFLD, including non-vegetarian diets, fried foods, spicy foods, and tea¹⁵. It
 138 was discovered that NAFLD patients had a greater prevalence of all components of the metabolic
 139 syndrome¹⁰. Finally, there are non-modifiable risk factors for south Asian NAFLD that are linked to
 140 genetic and epigenetic changes, such as SNPs¹⁶.

141 Interestingly, many research from South Asia show that NAFLD strikes young in this region, with an
 142 average age in the 40s and a male predominance^{16, 17}. In our study, among 35 participants, 48.6%
 143 participants were below 40 years old and 51.4% were between 40 to 60 years old. The mean age of the
 144 participants were 38.89 ± 8.50 years. There were fewer studies that looked at the link between other
 145 metabolic risk variables and incident severe liver disease, and the definitions of prognostic factors of
 146 relevance varied. As a result, pooling results was not possible, but the largest, highest-quality studies
 147 suggested that lipid abnormalities (low HDL and high triglycerides) and hypertension are both
 148 independently linked to incident severe liver disease. The corrected impact sizes appear to be similar to

149 those found in studies of people with a high BMI. There were fewer studies looking at the metabolic
150 syndrome, which is a collection of metabolic risk variables, as a predictor of liver outcomes.

151

152 CONCLUSION

153 NAFLD rates are increasing in lockstep with obesity and type 2 diabetes, posing an ever-increasing strain
154 on the health-care system. Increased knowledge of this problem among primary care physicians is critical
155 for reducing the disease's impact through metabolic risk factor screening and management. More
156 population-based research is needed to better understand the dangers and inform future public health
157 interventions.

158 REFERENCES

- 159 1. Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J,
160 Sanhueza E, Contreras C, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty
161 liver disease: An evidence-based clinical practice review. *World J Gastroenterol* 2014; 20:12182-
162 12201.
- 163 2. Zhang TS, Qin HL, Wang T, Li HT, Li H, Xia SH, Xiang ZH. Global publication trends and
164 research hotspots of nonalcoholic fatty liver disease: a bibliometric analysis and systematic
165 review. *Springer Plus* 2015; 4:776.
- 166 3. Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR. Ethnicity, and the
167 diagnosis gap in liver disease: a population-based study. *Br J Gen Pract* 2014; 694-702
- 168 4. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver
169 in children and adolescents. *Pediatrics* 2006; 118: 1388-1393 [PMID: 17015527 DOI: 10.1542/
170 peds.2006-1212]
- 171 5. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic
172 cirrhosis. *JAMA*. 2003; 289:3000-4.
- 173 6. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is
174 non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? *J*
175 *Gastroenterol Hepatol*. 2007; 22:788-93
- 176 7. Hoque MI. NAFLD in Bangladesh. *Abstract Book 1st Conference of SASL* 2013; 69.
- 177 8. Rahman MM, Kibria MG, Begum H, Haque M, Sultana N, Akhter M et al. Prevalence and Risk
178 Factors of Nonalcoholic Fatty Liver Disease in a Rural Community of South Asia.
179 *Gastroenterology* 2015; 148: S1045 - 6.
- 180 9. Ahmed F. Country report of Liver disease in Bangladesh. *Abstract Book 1st Conference of SASL*
181 2013; 45.
- 182 10. *Naim Alkhouri, MD, and Marsha H. Kay, MD, FACG, The Cleveland Clinic, Cleveland, OH -*
183 *Updated December 2012.*
- 184 11. *Ariel E. Feldstein, MD, and Marsha H. Kay, MD, FACG, Cleveland Clinic Foundation,*
185 *Cleveland, OH - Published January 2006.*
- 186 12. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of
187 nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes.
188 *Hepatology* 2016; 64: 73-84.
- 189 13. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver
190 disease in Asia, 1999-2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*
191 2019; 4: 389-98.

- 192 14. Wang L, Guo J, Lu J. Risk factor compositions of nonalcoholic fatty liver disease change with
193 body mass index in males and females. *Oncotarget* 2016; 7: 35632-42.
- 194 15. Choi YJ, Lee DH, Han KD, et al. Is nonalcoholic fatty liver disease associated with the
195 development of prostate cancer? A nationwide study with 10,516,985 Korean men. *PLoS One*
196 2018; 13: e0201308.
- 197 16. Yu D, Shu XO, Xiang YB, et al. Higher dietary choline intake is associated with lower risk of
198 nonalcoholic fatty liver in normalweight Chinese women. *J Nutr* 2014; 144: 2034-40.
- 199 17. Yu XY. The association between body mass index and non-alcoholic fatty liver disease. *J*
200 *Zhejiang Univ Med Sci* 2014; 43: 546-52.

UNDER PEER REVIEW